Press Releases
| Nine Biopharm won the ‘Minister of Health and Welfare Award’ at the ‘2023 Health Industry Performance Exchange’ | |||
|---|---|---|---|
| Writer | 관리자 | Search | 105 |
| Date | 2023-12-04 | ||
| Attachments | |||
 Nine Biopharm (CEO Kim Jae-hwan), a venture company developing biomaterials, announced on the 30th that it had received the ‘Minister of Health and Welfare Award’. On this day, at the '2023 Health Industry Performance Exchange', under the theme of one year's performance of the health industry and future leap forward, individuals and excellent organizations that have greatly contributed to the development of the health industry were selected and awarded a commendation from the Minister of Health and Welfare. Nine Biopharm, which attended the event, was selected as an innovative medical device company and received the ‘Minister of Health and Welfare Award’. Nine Biopharmaceuticals announced its success in developing 4th generation functional peptide medical device products and obtaining a medical device manufacturing license (export license) from the Ministry of Food and Drug Safety through the ‘Biohealth Investment Infrastructure Linked R&D Project’ hosted by the Korea Health Industry Development Institute. Currently developed Regenin® is a 4th generation functional peptide medical device product. Nine Biopharmaceuticals plans to begin its overseas business expansion through domestic and European CE certification for Regenin®. An official said, “Based on the original technology acquired through this business, we are launching Regenin® Skin Booster and Regenin® S products, which are high-efficacy aesthetic products, and are in full swing with overseas exports.” He added, “We are planning to launch new products for whitening and hair aesthetics in the future.” “We plan to launch it,” he said. Meanwhile, Nine Biopharmaceuticals is continuously developing materials for commercialization such as pharmaceuticals, medical devices, and cosmetics based on its proprietary peptide development platform technology, and in recognition of its technological prowess and business feasibility, it completed a Series A investment round worth KRW 8 billion from an investment institution. We are currently seeking additional investment to expand our business. Hankyung.com Newsroom open@hankyung.com https://n.news.naver.com/article/015/0004920243?sid=101 |
|||
